alexa Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer
Oncology

Oncology

Breast Cancer: Current Research

Author(s): Bedard PL, PiccartGebhart MJ

Abstract Share this page

Results are now available from 6 trials randomizing > 14,000 women with HER2-positive early breast cancer to trastuzumab versus non-trastuzumab-based adjuvant chemotherapy. Aside from the recently presented PACS 04 trial, these studies demonstrate remarkably consistent results: the addition of trastuzumab reduces recurrence by approximately 50% and improves overall survival by 30%, irrespective of tumor size, nodal status, schedule of administration, and type of chemotherapy administered. There remain many unanswered questions regarding optimal adjuvant trastuzumab use, including the relationship between trastuzumab efficacy and markers of HER2 assessment (HER2 protein expression, gene copy number, and chromosome 17 polysomy); the selection of patients for non-anthracycline-based chemotherapy; the decision to administer trastuzumab in a sequential or concurrent manner with chemotherapy; and the minimal effective duration of trastuzumab required for adjuvant therapy. Future studies with novel anti-HER2 strategies will prospectively evaluate biomarkers in an effort to further improve the outcome of women diagnosed with HER2-positive disease. This article was published in Clin Breast Cancer 8 Suppl and referenced in Breast Cancer: Current Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version